Physician profile
Travis Lee Taylor
NPI 1134110851
$1,612.72
in general payments reported to CMS, 2019-2025
9 companies · $380 in 2025
The $380 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $83.76 · 2021: $112 · 2022: $39.01 · 2023: $16.32 · 2024: $307 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $392.91 | 2024-2025 | Infuse, Biotrue One Day, Vyzulta |
| Alcon Vision LLC | $335.38 | 2019-2023 | Total30 |
| Sun Pharmaceutical Industries INC. | $322.13 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $204.78 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $118.42 | 2019-2021 | |
| Dompe US, INC. | $117.19 | 2024 | Oxervate |
| Optos, INC. | $98.64 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.27 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,244.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.